Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Conceptualising the experience of having TB: a global qualitative study.

IJTLD open·2026

Same author

Traceability and comparability through crosswalks with the NeuroMET Memory Metric.

Scientific reports·2023

Same author

Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry.

EJNMMI physics·2021

Same author

Biomarker-guided trials: Challenges in practice.

Contemporary clinical trials communications·2019

Same author

[Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].

Der Internist·2017

Same author

Third-order thermo-mechanical properties for packs of Platonic solids using statistical micromechanics.

Proceedings. Mathematical, physical, and engineering sciences·2016

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Sarcoidosis in Australia.

A Gillman¹, C Steinfort

¹Department of Respiratory medicine, Geelong Hospital, Geelong, Victoria, Australia. andrewjg@hotmail.com

Internal Medicine Journal

|May 31, 2007

Summary

This study reports the first incidence of sarcoidosis in Australia, revealing a static rate of 4.4-6.3 per 100,000. The findings detail the multi-system nature of this disease and its clinical characteristics in the Australian population.

Area of Science:

Pulmonology
Epidemiology
Rheumatology

Background:

The incidence of sarcoidosis in Australia remains undocumented.
Clinical features, diagnostic strategies, and treatment of Australian sarcoidosis patients are poorly characterized.

Purpose of the Study:

To determine the incidence of sarcoidosis in a regional Australian population.
To describe the clinical features, diagnostic methods, and treatment of sarcoidosis in Australia.

Main Methods:

Retrospective analysis of 122 sarcoidosis patient records from a respiratory service.
Study period: 1995-2005, serving a population of approximately 200,000.

Main Results:

Static incidence of 4.4–6.3 per 100,000 (2000-2005).

Related Experiment Videos

Last Updated: Jul 14, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Predominantly affected women (55%) and current smokers (28%).

Commonly involved systems: lung parenchyma (66%), thoracic adenopathy (58%), skin (22%), ocular (18%). Histological confirmation in 69%.

Conclusions:

Sarcoidosis is a multi-system disease of unknown cause in Australia.
Incidence is comparable to US studies of predominantly white populations.
A multicenter database is recommended for improved identification, description, and treatment.